|Bid||2.4700 x 1300|
|Ask||2.5700 x 4000|
|Day's Range||2.4650 - 2.5650|
|52 Week Range||2.0900 - 3.8600|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 02, 2016|
|1y Target Est||2.50|
Please note that a slide presentation to accompany management's prepared remarks is available in the Investor Relations section of the PDL website at pdl.com. Joining me today from PDL BioPharma are Dominique Monnet, President and CEO; Edward Imbrogno, Vice President and CFO; and Chris Stone, Vice President and General Counsel. Please turn to Slide 2 and let me remind you that during this call management will be making forward-looking statements regarding the Company's financial performance and other matters and actual results may differ materially from those expressed in or implied by the forward-looking statements.
Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06.Revenue of $4,115,000 declined by 90.68% from the same period last year, which missed the estimate of $5,500,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on PDLIPDL BioPharma hasn't issued any revenue guidance for the time being.Technicals Company's 52-week high was at $3.86Company's 52-week low was at $2.09Price action over last quarter: down 17.60%Company Description PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.See more from Benzinga * Click here for options trades from Benzinga * Recap: TELA Bio Q3 Earnings * Recap: Beyond Air Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.